Connexins enable direct intercellular communication of metabolites, nucleotides, nutrients, and secondary messengers, regulating apoptosis, inflammation, and cellular growth, while also amplifying liver inflammation and cell death (Maes and Vinken 2017
For this reason, patients taking these forms should always consult with a medical professional
While the benefits of glutathione are well-documented, it's important to consider the potential risks associated with its use
They are the: Phase III study of Exenatide in Parkinsons study in the UK Phase II study of Liraglutide in Parkinsons study in Los Angeles Phase II study of Lixisenatide in Parkinsons study in France Phase II study of Semaglutide in Parkinsons study in Norway Phase II study of NLY01 in Parkinsons study across the USA (being conducted by Neuraly) Phase II study of PT320 in Parkinsons in South Korea (being conducted by Peptron) Phase II study of Exenatide trial in Parkinsons in Sweden Phase I study of Exenatide in Parkinsons study in Florida In addition, I am aware of other interested parties looking to enter this space, so over the next few years we will be seeing a great deal of clinical trial data dealing with GLP-1R agonists in Parkinsons